<DOC>
	<DOCNO>NCT02814500</DOCNO>
	<brief_summary>An open label , randomize , 2-sequence , 2-period , single-dose cross-over study evaluate pharmacokinetics characteristic DP-R212</brief_summary>
	<brief_title>DP-R212 Pharmacokinetic Study Phase I</brief_title>
	<detailed_description>An open label , randomize , 2-sequence , 2-period , single-dose cross-over study evaluate pharmacokinetics characteristic DP-R212 , fix dose combination compare coadministration separate constituent healthy adult volunteer</detailed_description>
	<mesh_term>Amlodipine</mesh_term>
	<mesh_term>Rosuvastatin Calcium</mesh_term>
	<criteria>BMI 17.5~30.5 sign inform consent form prior study participation Clinically significant disease Previously donate whole blood within 60 day component blood within 30 day Clinically significant allergic disease Taken IP trial within 90 day An impossible one participate clinical trial investigator 's decision include laboratory test result</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>